Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Smithkline Beecham Biologicals S.a.

Other

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Reinhard Wallich

Markus M Simon

Michael D Kramer

Ulrich E Schaible

Yves Lobet

Weimin Zhong

A pharmaceutical composition for treating Lyme disease contains an antibody as an active agent which is specific for the 24 kDa antigen (OspC) of , preferably an antibody which is specific for the 24 kDa antigen (OspC) of having the sequence shown in SEQ ID NO.2.

Medicament for treating a manifested lyme disease

The invention related to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with know OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.

Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines

Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and

The invention relates to novet Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.

Growing community of inventors

Heidelberg, Germany

Reinhard Wallich